Bioven Emerges from Stealth with Phase III Cancer Vaccine
By Nuala Moran
Wednesday, September 5, 2012
LONDON – A company based in Aberdeen, Scotland, that was founded and funded in Malaysia, with the aim of commercializing cancer vaccines discovered in Cuba, has announced the start of a pivotal Phase III trial of its lead product, BV-NSCLC-001.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.